Brussels (Belgium), 28 July 2016 – 7:00 (CEST) – regulated information –
UCB Half Year Report 2016:

UCB continues to deliver on its growth strategy

- Continued core product growth drive top and bottom line
- UCB's epilepsy franchise strengthened by Briviact® launch in the EU and North America; Vimpat® for epilepsy approved in Japan
- Continued increased focus on core business: nitrates business divested
- R&D update: BLA to FDA submitted for *romosozumab*
- Financial outlook 2016 confirmed: Revenue expected at approximately € 4.0-4.1 billion, recurring EBITDA of € 970–1 010 million, Core EPS in the range of € 2.90-3.20.

"The continued growth of UCB in the first half of 2016 is the outcome of our strategy which aims to deliver superior value to patients," said Jean-Christophe Tellier, CEO UCB. "We also grow our epilepsy portfolio with the ongoing launch of Briviact® in the EU and North America and the approval of Vimpat® in Japan. We continue the preparations with our partner to make *romosozumab* available to people living with osteoporosis and to invest into our promising early pipeline to deliver future breakthrough solutions for patients."

UCB Financial Results HY 2016:

€ million	HY 2016	HY 2015	Actual	CER[1]
Revenue	**2,019**	**1,917**	5%	5%
Net sales	**1,876**	**1,704**	10%	9%
rEBITDA[2]	**549**	**464**	18%	11%
Core EPS[3] (€)	**1.72**	**1.18**	46%	34%

In the first six months of 2016, **revenue and net sales** continued its growth driven by product growth: Cimzia®, Vimpat® and Neupro® combined reached net sales of € 1.12 billion, a plus of 19%.

18% higher **underlying profitability (recurring EBITDA[2])** of € 549 million reflecting continued higher revenue and a lower operating expenses ratio.

Profit for the Group amounted to € 316 million, a plus of 9%, of which € 300 million is attributable to UCB shareholders.



[1] CER = constant exchange rates
[2] rEBITDA = recurring Earnings Before Interest, Taxes, Depreciation and Amortization
[3] Core EPS = Core Earnings Per Share

R&D update

Neurology

Briviact® (*brivaracetam*) as adjunctive therapy for partial-onset seizures in patients from 16 years of age was approved in EU in January and in the U.S. in February 2016 and received U.S. Drug Enforcement Administration (DEA) scheduling in May 2016. Briviact® is now available to patients with epilepsy in the EU and in North America.

In July 2016, the Japanese regulatory authorities approved **Vimpat®** (*lacosamide*) as adjunctive therapy in the treatment of partial-onset seizures in adult patients with epilepsy.

Immunology

In May 2016, ***seletalisib*** started a Phase 1b study in activated PI3 kinase delta syndrome (APDS), a rare cause of immunodeficiency. The Phase 2a study in patients with primary Sjogren's syndrome (pSS) which started in November 2015 is ongoing with first results expected in H1 2017.

In June, positive results from a Phase 1b study in patients with psoriatic arthritis (PsA) were presented at EULAR (Annual European Congress of Rheumatology) for ***bimekizumab***, an investigational humanized IgG1 monoclonal antibody specifically designed to potently and selectively inhibit the biological function of both IL-17A and IL-17F, two key proinflammatory cytokines. IL-17A and IL-17F are involved in chronic inflammatory processes that drive many severe skin and joint diseases. Phase 2b studies for *bimekizumab* will start this year.

In June, the Phase 2b program started for ***dapirolizumab pegol***, an anti-CD40L pegylated Fab being developed in systemic lupus erythematosus jointly with Biogen. The dose-ranging study aims to enroll around 160 patients for 12 months. First results are expected in H2 2018.

In June, a Phase 1 study successfully completed with **UCB4144/VR942**, an immunomodulatory inhaled biologic for patients with uncontrolled asthma in development partnership with Vectura. The generated data package supports the continued development of UCB4144/VR942 and progression of Phase 2 preparative activities.

Bone

In February, UCB and Amgen announced positive top-line results from a Phase 3 study evaluating ***romosozumab*** in postmenopausal women with osteoporosis (FRAME), which met the co-primary endpoints of reducing the incidence of new vertebral fracture through months 12 and 24.

UCB and Amgen also announced in March positive top-line results from a Phase 3 study evaluating *romosozumab* in men with osteoporosis (BRIDGE), which met the primary endpoint of increasing bone mineral density at the lumbar spine at 12 months.

In July, UCB and Amgen submitted the biologics license application (BLA) for romosozumab to the U.S. FDA, based on the FRAME study results in postmenopausal women with osteoporosis.

All other clinical development programs are continuing as planned.

Net sales

€ million	HY 2016	HY 2015	Actual	CER[1]
U.S.	371	321	16%	16%
Europe	169	137	23%	25%
Japan	19	4	>100%	>100%
International markets	42	29	44%	55%
Total Cimzia®	**602**	**490**	**23%**	**24%**

Cimzia® (*certolizumab pegol*) net sales of € 602 million are driven by continuously broadened access to patients living with inflammatory TNF mediated diseases in all markets where Cimzia® is available to patients. Net sales in Japan are reflecting sustainable in-market demand.

Net sales in **neurology** compiling net sales of Vimpat®, Keppra® and Briviact® as well as Neupro® and other are up 5% to € 876 million.

UCB's epilepsy franchise is strengthened by the ongoing launch of **Briviact®** (*brivaracetam*) in the EU since January and the U.S. since June with net sales of € 7 million.

€ million	HY 2016	HY 2015	Actual	CER
U.S.	288	244	18%	18%
Europe	74	64	15%	16%
International markets	18	14	23%	33%
Total Vimpat®	**379**	**323**	**18%**	**18%**

Vimpat® (*lacosamide*) is reaching more and more people living with epilepsy in all markets and achieved net sales of € 379 million.

€ million	HY 2016	HY 2015	Actual	CER
U.S.	99	124	-21%	-20%
Europe	122	127	-3%	-3%
Japan	48	51	-5%	-12%
International markets	85	83	2%	11%
Total Keppra®	**354**	**385**	**-8%**	**-7%**

Keppra® (*levetiracetam*) for epilepsy net sales were € 354 million, down by 8%. In 2015 and in the U.S., net sales benefited from stocking effects. In Japan, E Keppra® shows continued in-market growth while net sales reflect shipment patterns.

€ million	HY 2016	HY 2015	Actual	CER
U.S.	38	36	5%	5%
Europe	79	73	8%	9%
Japan	19	15	31%	31%
International markets	7	5	47%	59%
Total Neupro®	**143**	**129**	**11%**	**12%**

Neupro® (*rotigotine*), the patch for Parkinson's disease and restless legs syndrome, continued its growth trend and reached net sales of € 143 million.

[1] CER = constant exchange rates
[2] rEBITDA = recurring Earnings Before Interest, Taxes, Depreciation and Amortization
[3] Core EPS = Core Earnings Per Share

Revenue and net sales increased to € 2.0 billion (+5%; +5% CER) and € 1.9 billion (+10%; +9% CER) respectively driven by continued core product growth.

Royalty income went down to € 51 million (-40%; -38% CER) due to patent expirations, royalty adjustment for *fesoterodine* and divestment. **Other revenue** decreased to € 92 million (-28%; -27% CER), mainly due to lower milestone payments received in H1 2016 compared to H1 2015.

Gross profit increased to € 1.45 billion (+6%, +4% CER), due to net sales growth and the improved product mix. Operating expenses decreased by 2% reaching € 1.02 billion (0% CER). This reflects 4% higher marketing and selling expenses of € 451 million, 2% lower research and development expenses of € 458 million and 12% lower general and administrative expenses of € 87 million.

Underlying profitability –recurring EBITDA[2]- reached € 549 million (+18%; +11% CER), driven by the higher gross profit and the decrease of operating expenses in the first six months 2016.

Non-recurring income was € 50 million after € 80 million, a gain from the divestiture of UCB's nitrates established brands (€ 75 million) offset with an impairment of oncology molecules and other non-recurring charges. **Net financial expenses** increased to € 65 million from € 47 million, which was driven by an impairment of the Lannett warrants received in connection with the Kremers Urban divestiture in November 2015. **Income tax** expenses were € 91 million reflecting an average tax rate on recurring activities of 25%. **Profit/loss from discontinued operations**, reflecting the divestiture and activities respectively of Kremers Urban, reached a loss of € 9 million after a profit of € 28 million in 2015. In November 2015, the divestiture of UCB's U.S. specialty generics business, Kremers Urban, to Lannett was successfully closed.

Profit of the Group was € 316 million (+9%; 0% CER) of which € 300 million is attributable to UCB shareholders and € 16 million to non-controlling interests. For the first six months 2015, profit was € 289 million, which included profit from discontinued operations, and of which € 267 million were attributable to UCB shareholders and € 22 million to non-controlling interests.

Core earnings per share, which reflect profit attributable to UCB shareholders after tax effects of non-recurring items, financial one-offs and amortization of intangibles, reached € 1.72 per share based on 188 million weighted average shares outstanding from € 1.18 per share based on 192 million shares in HY 2015. (+46%; +34% CER)

Outlook 2016 confirmed - UCB expects continued growth. 2016 revenue should reach approximately € 4.0 - 4.1 billion; recurring EBITDA[2] should increase to approximately € 970 - 1 010 million. Core earnings per share are expected in the range of € 2.90 - 3.20 based on an expected average of 188 million shares outstanding.

HY 2016 – Financial highlights

Find the full financial reports on the UCB website: www.ucb.com/investors/Financials/

For the six months ended 30 June[1]	Actual		Variance	
€ million	**2016**	2015	Actual rates	CER
Revenue	**2 019**	**1 917**	**5%**	**5%**
Net sales	1 876	1 704	10%	9%
Royalty income and fees	51	85	-40%	-38%
Other revenue	92	128	-28%	-27%
Gross profit	**1 447**	**1 369**	**6%**	**4%**
Marketing and selling expenses	-451	-433	4%	6%
Research and development expenses	-458	-472	-3%	-2%
General and administrative expenses	-87	-99	-12%	-11%
Other operating income / expenses (-)	-19	-31	-39%	-39%
Recurring EBIT (REBIT)	**432**	**335**	**29%**	**18%**
Non-recurring income / expenses (-)	50	80	-37%	-39%
EBIT (operating profit)	**482**	**415**	**16%**	**7%**
Net financial expenses (-)	-65	-47	40%	40%
Share of net profits of associates	0	1	-89%	-89%
Profit before income taxes	**417**	**369**	**13%**	**3%**
Income tax expenses (-) / credit	-91	-108	-16%	-23%
Profit from continuing operations	**325**	**261**	25%	14%
Profit / loss (-) from discontinued operations	-9	28	N.A.	N.A.
Net profit	**316**	**289**	**9%**	**0%**
Attributable to UCB shareholders	300	267	12%	0%
Attributable to non-controlling interest	16	22	-27%	-27%
Recurring EBITDA	**549**	**464**	**18%**	**11%**
Capital expenditures (including intangible assets)	71	97	-27%	N.A.
Net financial debt[2]	1 346	921	46%	N.A.
Cash flow from continuing operating activities[3]	258	145	>100%	N.A.
Weighted average number of shares (non-diluted)	**188**	**192**	-2%	N.A.
EPS (€ per weighted average number of shares - non diluted)	**1.59**	**1.39**	**15%**	N.A.
Core EPS (€ per weighted average number of shares - non diluted)	**1.72**	**1.18**	**46%**	**34%**

CER: constant exchange rates

1 Due to rounding, some financial data may not add up

2 Except for the net financial debt, where 2015 relates to balance as at 31 December 2015.

3 Interest received has been presented as part of net cash flow generated from operating activities (see cash flow statement)

"The statutory auditor has issued an unqualified review report dated 27 July 2016 on the company's condensed consolidated interim financial statements as of and for the six month period ended 30 June 2016, and has confirmed that the accounting data reported in the press release is consistent, in all material respects, with the accounts from which it has been derived."

For further information

Investor Relations

Antje Witte, Investor Relations, UCB
T +32.2.559.94.14, antje.witte@ucb.com

Isabelle Ghellynck, Investor Relations, UCB
T+32.2.559.9588, isabelle.ghellynck@ucb.com

Corporate Communications

France Nivelle, Global Communications, UCB
T +32.2.559.9178, france.nivelle@ucb.com

Laurent Schots, Media Relations, UCB
T+32.2.559.92.64, laurent.schots@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7 700 people in approximately 40 countries, the company generated revenue of € 3.9 billion in 2015. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news

Forward looking statements

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees.

Additionally, information contained in this document shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any offer, solicitation or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction. UCB is providing this information as of the date of this document and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.

There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.

Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.